SRRA - シエラ・オンコロジ― (Sierra Oncology Inc.)

SRRAのニュース

   Astrazeneca PLC – Consensus Indicates Potential 1.0% Upside  2022/04/04 10:08:31 DirectorsTalk
Astrazeneca PLC with ticker code (AZN) now have 5 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 70 and 59.5 and has a mean target at 66.98. With the stocks previous close at 66.34 this would indicate that there is a potential upside of 1.0%. There is a 50 day moving average of 60.54 while the 200 day moving average is 59.03. The market cap for the company is $207,036m. You can visit the company''s website by visiting: https://www.astrazeneca.com [stock_market_widget type="chart" template="basic" color="green" assets="AZN" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $209,034m based on the market concensus. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
   Astrazeneca PLC – Consensus Indicates Potential 1.5% Upside  2022/03/28 08:37:08 DirectorsTalk
Astrazeneca PLC with ticker code (AZN) have now 5 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 70 and 59.5 with a mean TP of 66.98. Given that the stocks previous close was at 66.02 this indicates there is a potential upside of 1.5%. The 50 day moving average now sits at 59.84 and the 200 day MA is 58.83. The company has a market cap of $201,830m. Find out more information at: https://www.astrazeneca.com [stock_market_widget type="chart" template="basic" color="green" assets="AZN" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $204,765m based on the market concensus. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
   Astrazeneca PLC – Consensus Indicates Potential 5.9% Upside  2022/03/21 15:41:48 DirectorsTalk
Astrazeneca PLC found using ticker (AZN) now have 5 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 70 and 59.5 with a mean TP of 66.98. Now with the previous closing price of 63.23 this is indicating there is a potential upside of 5.9%. The 50 day moving average now sits at 59.15 and the 200 day MA is 58.65. The company has a market cap of $196,144m. Find out more information at: https://www.astrazeneca.com [stock_market_widget type="chart" template="basic" color="green" assets="AZN" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $207,776m based on the market concensus. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products lude Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
   Astrazeneca PLC – Consensus Indicates Potential 10.0% Upside  2022/03/14 08:06:41 DirectorsTalk
Astrazeneca PLC found using ticker (AZN) have now 5 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 70 and 59.5 calculating the average target price we see 66.98. Given that the stocks previous close was at 60.9 this now indicates there is a potential upside of 10.0%. The day 50 moving average is 58.73 and the 200 moving average now moves to 58.51. The market cap for the company is $188,315m. Find out more information at: https://www.astrazeneca.com [stock_market_widget type="chart" template="basic" color="green" assets=AZN" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $207,116m based on the market concensus. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
   Sierra Oncology Non-GAAP EPS of -$1.44  2022/03/10 12:45:14 Seeking Alpha
Sierra Oncology press release (SRRA): Q4 Non-GAAP EPS of -$1.44. Cash and cash equivalents totaled $104.7 million as of December 31, 2021, compared to $104.1 million as of December…
   Sierra Oncology to Present at Three September Investor Conferences  2021/09/07 11:00:00 Business Wire
SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced the company will participate in three investor conferences in September 2021. Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Sierra Oncology will provide a company update at the HC Wainwright 23rd Annual Global Investment Conference and the Oppenheimer Fall Healthcare Life
   Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)  2021/09/03 20:05:00 Business Wire
SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, granted stock options to five new employees as approved by the Compensation Committee of the Companys Board of Directors, under Sierra Oncologys 2018 Equity Inducement Plan. The 2018 Equity Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individual
   Sierra Oncology accelerates planned filing of myelofibrosis candidate momelotinib  2021/08/09 12:08:29 Seeking Alpha
   Sierra Oncology Provides Update to Momelotinib Development Timeline and Closes on $34 Million in Additional Funding  2021/08/09 11:00:00 Business Wire
SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today updated guidance on the development timeline for its lead product candidate, momelotinib. The company now expects topline data from the Phase 3 registration-enabling MOMENTUM study by February 2022, and assuming positive results, the company plans to file a New Drug Application with the U.S. Food &
   Sierra Oncology Bets $216M On AstraZeneca''s BET Inhibitor For Myelofibrosis  2021/08/06 12:06:55 Benzinga
Sierra Oncology Inc (NASDAQ: SRRA ) has acquired an exclusive global license from AstraZeneca Plc (NASDAQ: AZN ) for AZD5153, a potent, and selective BRD4 BET inhibitor with a novel bivalent binding mode. Sierra plans to initiate a Phase 2 study evaluating momelotinib in combination with AZD5153 in myelofibrosis patients in 1H of 2022. Under the agreement terms, Full story available on Benzinga.com

calendar